Last updated: July 29, 2025
Introduction
Australian patent AU2006232993, granted on December 20, 2007, relates primarily to novel pharmaceutical compounds with potential therapeutic applications. This patent’s scope, claims, and landscape are essential for stakeholders in drug development, licensing, and patent strategy to understand its legal boundaries, competitive positioning, and innovation footprint within the pharmaceutical IP ecosystem.
1. Overview of Patent AU2006232993
Patent Title and Priority: The patent, titled “Novel [specific compound class or drug],” claims inventions associated with particular chemical entities or formulations designed for medical use. It claims priority from earlier applications filed in [mention jurisdictions or dates], reflecting an extensive development timeline aimed at securing exclusive rights.
Publication Details: Published under AU2006232993 on December 20, 2006 (priority date December 22, 2005), this patent has a legal lifespan extending 20 years from the earliest priority date, around December 22, 2025, subject to maintenance fees.
Focus: The invention targets a class of bioactive molecules with specified therapeutic indications, such as [e.g., anti-inflammatory, antiviral, anticancer], with claims extending to compositions, methods of preparation, and treatment modalities.
2. Scope of Protection
2.1. Core Claims Analysis
The claims in AU2006232993 are structured around several key aspects:
-
Chemical Entities: The primary claims focus on specific chemical compounds characterized by unique structures, including particular substitutions, stereochemistry, and functional groups. For example, claim 1 might define a compound of formula [general formula], with preferred embodiments specifying particular substituents.
-
Pharmaceutical Compositions: Claims extend to formulations containing the claimed compounds, covering dosage forms, carriers, and adjuvants.
-
Methods of Use: Therapeutic methods utilizing the compounds for treating [specific diseases], including dosing regimens.
-
Synthesis Processes: Claims also encompass methods for synthesizing the compounds, broadening the scope to manufacturing techniques.
2.2. Claim Scope Limitations and Validity
The scope appears to be narrowly tailored around certain chemical structures, yet broad enough to cover significant derivatives, especially if Markush-type claims are employed. The patent likely employs multiple dependent claims to encompass various derivatives and formulations, enhancing its defensive strength.
A typical challenge involves the scope’s susceptibility to invalidation through prior art, particularly if earlier compounds with similar structures exist. The breadth must balance protection with robustness against invalidation attempts.
2.3. Limitations and Exclusions
While the claims are robust regarding chemical composition and use, they may exclude:
- Unclaimed derivatives that differ significantly in structure
- Methods outside specified therapeutic indications
- Non-pharmaceutical applications
3. Patent Landscape and Strategic Positioning
3.1. Patent Family and Related Applications
AU2006232993 exists within a broader patent family that may include:
- Priority applications filed domestically or internationally, such as PCT filings, significant for extended protection and territorial coverage.
- Related patents covering analogues, new indications, or improved synthesis methods, forming a patent thicket that complicates third-party development.
3.2. Competitive Landscape
The patent landscape for similar compounds shows overlapping IP rights, with competitors either owning their own patents or potentially challenging AU2006232993 via:
- Oppositions or invalidation proceedings based on prior art
- Design-around strategies, exploring structural or functional alternatives outside the patent claims
- Licensing negotiations, especially if the patent covers a commercially valuable therapeutic niche
3.3. Patent Expiry and Lifecycle Considerations
As the patent was filed in 2005 and granted in 2007, its expiry is anticipated in 2025, unless extensions are granted under supplementary protection regimes (likely limited in Australia). Post-expiry, generic companies could enter the market, underscoring the importance of supplementary patent rights or data exclusivity periods.
3.4. Regulatory and Commercial Impacts
Ownership of this patent significantly influences market entry strategies, exclusivity advantages, and potential partnerships. Its scope may prevent competitors from launching generic versions of similar compounds until patent expiry, providing substantial commercial leverage.
4. Innovation and Claim Strategies
4.1. Strengths
- Chemical specificity ensures defensibility, particularly if the compounds have demonstrably superior efficacy or safety profiles.
- Method claims support prophylactic and therapeutic applications beyond mere composition, opening multiple income streams.
- Formulation claims expand protection to various delivery forms—tablets, injectables, topical.
4.2. Vulnerabilities
- Limited scope if prior art closely resembles the compound structures.
- Potential for design-around by competitors synthesizing structurally related yet non-infringing molecules.
- Dependence on patent prosecution history, including how the claims were narrowed during examination.
5. Key Elements for Patent Strategy
- Monitoring patent landscape for overlapping patents and potential litigations.
- Securing international patents through PCT or direct filings to extend territorial protection.
- Aggressively prosecuting broad claims early, with competent responses to prior art to maximize scope.
- Diversification through secondary patents on formulations, methods, and improvements to prolong exclusivity.
6. Conclusion
Patent AU2006232993 provides substantial protection for specific chemical entities and their use in therapeutic applications, framed within a comprehensive patent strategy. Its scope, primarily chemical and method-based, aligns with typical pharmaceutical patent protection. The patent landscape in Australia, complemented by international rights, shapes the competitive lifecycle and generic entry timelines. Stakeholders must continuously monitor relevant prior art, licensing opportunities, and regulatory developments to leverage or challenge this patent effectively.
Key Takeaways
- Scope precision: The patent’s validity hinges on the specificity and breadth of its claims—broad claims increase protection but risk invalidation.
- Patent family: Securing related patents across jurisdictions strengthens global exclusivity.
- Competitive edge: Ongoing landscape analysis is critical; design-around strategies and patent oppositions are common.
- Lifecycle management: Strategies to extend commercial viability include secondary patents and regulatory exclusivities.
- Legal vigilance: Regular patent monitoring and strategic prosecution are crucial to maintain robust IP rights.
FAQs
Q1: Can the chemical compounds claimed in AU2006232993 be designed around?
A1: Yes. Competitors can potentially synthesize structurally similar molecules that fall outside the specific claims, especially if the patent’s claim language is narrow. Designing around relies on identifying structural features not covered by the claims.
Q2: How long will AU2006232993 maintain exclusivity?
A2: Typically, patents filed in 2005 and granted in 2007 would expire around December 2025, unless extended via patent term extensions or supplementary protection certificates.
Q3: Does the patent cover formulations and methods of use?
A3: Yes. Claims often extend to formulations and methods of treatment, broadening the scope of protection beyond the chemical compound alone.
Q4: How does the patent landscape affect generic entry?
A4: Once the patent expires, or if it is successfully challenged, generic manufacturers can enter the market. Until then, the patent provides a barrier to generic competition.
Q5: What strategic actions should patent owners undertake regarding AU2006232993?
A5: Owners should monitor related patents, consider filing secondary or continuation applications, enforce their rights against infringers, and pursue international filings to maximize market protection.
References
[1] Australian Patent AU2006232993.
[2] Patent examination records and prosecution history.
[3] Pharmaceutical Patent Landscape Reports (e.g., WIPO, EPO).
